
Edgewise Therapeutics Sells Muscular Dystrophy Portfolio to Servier
Edgewise Therapeutics has finalized the sale of its sevasemten program and muscular dystrophy business to the international pharmaceutical group Servier for $1.55 billion in upfront cash. The deal, which includes potential milestone payments totaling $1.1 billion, marks a definitive pivot for the company toward its cardiovascular drug pipeline.























/smstreet/media/media_files/2025/08/14/zoomcar-2025-08-14-16-46-51.png)


